Battle rages over access to new ‘miracle’ HIV drug

Lenacapavir, an injectable PrEP medication requiring only two annual doses, shows potential to nearly eliminate HIV infections globally. Despite World Health Organization recommendations for prioritised access, significant barriers persist. Experts at the Aids 2026 Conference in Rio de Janeiro, Brazil, highlight that dramatic declines in worldwide HIV prevention investment and specific USAID foreign aid cuts are preventing those in greatest need, particularly in Latin American countries where trials occurred, from accessing this innovation.